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L E T T E R TO TH E ED I TOR
A diagnosis of mycosis fungoides in a pediatric patient with recurrent
Langerhans cell histiocytosis
To the Editor:
An 8-year-old female presented with a reddish-brown papule that
tripled in size. She had a history of intermittent hypopigmentation
(Fig. 1A). Biopsy of the papule revealed a lymphohistiocytic infiltrate
with increased CD1a and S100-positive Langerhans cells, consistent
with Langerhans cell histiocytosis (LCH) (Fig. 1D). v-RAF murine sar-
coma viral oncogene homolog (BRAF) mutation testing was negative.
Workup for other sites of disease was negative.
There was minimal response to topical steroids. She began oral
prednisonewith partial response but flaredwith taper. Treatmentwith
oral methotrexate and prednisone1 resulted in complete response.
With discontinuation, she had recurrence of papules and hypopigmen-
tation. Repeat biopsy confirmed LCH. Methotrexate was resumed and
she had full resolution of papules but persistent hypopigmentation;
however, her papules recurred with discontinuation of therapy.
Repeat biopsy revealed atypical epidermotropic CD8-positive
T cells that displayed loss of CD2 and diminished expression of CD7
F IGURE 1 (A) Diffuse erythematous thin plaques with fine scale as well as hypopigmented macules on the anterior trunk, approximately 1 year
after the initial diagnosis. (B) Significant repigmentation of the hypopigmented lesions approximately 8 months after starting phototherapy. (C) A
biopsy of an erythematous papule in a background hypopigmented patch demonstrated cytologically atypical epidermotropic T cells (400×). (D)
An excision of a large and rapidly growing papule revealed numerous scattered and collected Langerhans cells with reniform nuclei, longitudinal
nuclear folds, and relatively abundant pale, eosinophilic cytoplasm (400×)
(Fig. 1C). A T-cell receptor gene rearrangement study identified a
clonal T-cell population. CD1a did not reveal increased Langerhans
cells. No clonal T-cell population was identified in prior biopsies.
The patient was diagnosed with hypopigmented mycosis fungoides
(MF), stage IB. She started treatment with topical triamcinolone and
narrowbandultravioletBwith complete resolutionof her hypopigmen-
tation (Fig. 1B).
LCH describes an abnormal proliferation of usually clonal LCs and
commonly occurs in children with varying clinical presentations. It is
thought to be an inflammatory myeloid neoplasm as there is a high
rate of recurrent mutations of the MAP2K pathway, and transcrip-
tional profiling suggests that LCs are similar to bone marrow derived
monocyte and dendritic cell precursors.2 Additionally, LCH has been
described to be associated with many other neoplasms3 and may pre-
cede, follow, or occur simultaneously. It is unclear in our patient which
entity occurred first as she had no prior biopsies of the hypopigmenta-
tion.
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Cutaneous T-cell lymphoma is a rare diseasewith an estimated inci-
dence of 10.2 per million persons.4,5 It is uncommon in children, with
peak incidence at 80 years.6 A review of the international Childhood
Registry for Cutaneous Lymphomas revealed increased incidence in
males and median age of diagnosis of 10 years.7 MF is the most com-
mon of the cutaneous T-cell lymphomas in all ages.8,9 It is typically pre-
sented as hypo- or hyperpigmented lesions, patches, plaques, or poik-
iloderma. Hypopigmented lesions predominate in younger patients.
A literature review highlights two cases of MF associated with
LCH.10 Both were older adult males diagnosed with MF with CD1a
and S100 positive LCs admixed within biopsy samples. These differ
from our case in that the nodules of LCs occurred concurrently, as
is common in cases of LCH-associated lymphoma. Interestingly, our
patient demonstrated LCH on early biopsies but all recent biopsies
showed MF without LCH. To our knowledge, this is the first pediatric
case of a patient with initial diagnosis of LCH, responsive to treatment
with multiple recurrences, and subsequent diagnosis of MF. This case
should prompt clinicians caring for patients with LCH to be vigilant for
the presence or development of hypopigmented patches/plaques that
could representMF and require a different treatment strategy.
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